Cancer Drug Prices Capped at 30%

Introduction to Cancer Treatment Costs in India

Cancer is a leading cause of catastrophic health spending in India, with out-of-pocket expenses accounting for 50-80% of direct treatment costs. The high costs of cancer care can lead patients to defer treatment or opt for cheaper alternatives, which can have severe consequences on their health and well-being.

Sarojini Nadimpally, a public health researcher, was diagnosed with HER2-positive breast cancer in June 2025 and was prescribed a targeted combination drug that cost around ₹2.7 lakh per dose. She needed 18 doses, making the total cost prohibitively expensive. This is just one example of the many patients in India who struggle to afford cancer treatment due to the high costs involved.

Background and Timeline of Cancer Drug Price Regulation

The Indian government has been working to regulate cancer drug prices for several years. In 2019, the government capped trade margins on 42 non-scheduled anti-cancer drugs. The recent decision to cap trade margins on 137 non-scheduled anti-cancer drugs at 30% is an extension of this effort.

Cancer Drug Price Caps: A Welcome Step

The Indian government's decision to cap trade margins on non-scheduled anti-cancer drugs is expected to save patients around ₹2,500 crore annually. The cap takes effect on November 9, and manufacturers are required to report formulation-level information, including brand name, composition, pack size, and revised MRP.

Experts argue that the permitted margin is a sizeable mark-up, especially for expensive drugs. The government is putting a ceiling on the profit, not the underlying price, and it remains to be seen how this cap will actually reduce what patients pay. However, this move is seen as a welcome step towards making cancer treatment more affordable in India.

Expert Perspectives on Cancer Drug Price Regulation

Dr. Vedant Kabra, principal director of surgical oncology at Fortis Memorial Research Institute, says that high costs of treatments can lead patients to defer treatment or opt for cheaper alternatives. For example, a lifetime course of osimertinib, a drug used to treat EGFR-mutated lung cancer, costs around ₹1.25 lakh per month, which is beyond the reach of many patients.

Dr. Narayanankutty Warrier, senior consultant oncologist at MVR Cancer Centre and Research Institute, says that patients often switch to cheaper alternatives, which can lead to disease progression. He argues that even a slight improvement in survival means that new-generation drugs become monopoly drugs, making them unaffordable for many patients.

Pricing Conundrum: A Complex Issue

The National Pharmaceutical Pricing Authority (NPPA) has set a common trade-margin ceiling on a broad range of cancer medicines, including patented, chemotherapy, targeted, immunotherapy, hormonal, and blood cancer drugs. Manufacturers are required to report formulation-level information, including brand name, composition, pack size, and revised MRP.

Experts argue that the permitted margin is a sizeable mark-up, especially for expensive drugs. The government is putting a ceiling on the profit, not the underlying price, and it remains to be seen how this cap will actually reduce what patients pay. The pricing conundrum is a complex issue, with many factors at play, including the cost of production, distribution, and marketing.

Read also: Stroke Symptoms: Types, Treatment, and Recovery

Read also: Wake-Up Strokes: Timely Treatment

Challenges Ahead: Implementing the Cap

Malini Aisola, co-convener of the All India Drug Action Network, says that the mark-up for cancer medicines is unjustified and that hospitals and distributors get to keep nearly all the margin. She argues that the government should use its legal powers to increase competition and reduce prices.

Dr. Indranil Mukhopadhyay, a healthcare expert, says that India needs a smarter healthcare margin policy and that the government should consider off-patent options, pooled procurement, and value-based pricing to curb costs. The implementation of the trade margin cap will be crucial in determining its effectiveness in reducing cancer treatment costs.

Implications for Readers in India

The Indian government's decision to cap trade margins on non-scheduled anti-cancer drugs has significant implications for readers in India. Cancer patients and their families will be directly affected by this decision, and it is essential to understand the potential benefits and limitations of this policy.

What to Watch Next

The implementation of the trade margin cap will be closely watched by healthcare experts, patients, and the pharmaceutical industry. The government's decision to cap trade margins on non-scheduled anti-cancer drugs is a step in the right direction, but it remains to be seen how this policy will be enforced and what its actual impact will be on cancer treatment costs.

• Cancer is a leading cause of catastrophic health spending in India.
• The high costs of cancer care can lead patients to defer treatment or opt for cheaper alternatives.
• The Indian government has capped trade margins on 137 non-scheduled anti-cancer drugs at 30%.
• Experts argue that the permitted margin is a sizeable mark-up, especially for expensive drugs.
• The implementation of the trade margin cap will be crucial in determining its effectiveness in reducing cancer treatment costs.

Key Figures: ₹2,500 crore (expected annual savings for patients), 30% (trade margin cap), 50-80% (out-of-pocket expenses for cancer treatment), ₹1.25 lakh (monthly cost of osimertinib), ₹2.7 lakh (cost of targeted combination drug per dose).